Login / Signup

BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice.

Vicente VillanuevaFrancisco Javier López-GonzálezJosé Angel MauriJuan Rodriguez-UrangaMarta Olivé-GadeaJavier MontoyaJesus Ruiz-GiménezJorge Zuritanull null
Published in: Acta neurologica Scandinavica (2018)
In a large population of patients with predominantly drug-resistant epilepsy, brivaracetam was effective and well-tolerated; no unexpected AEs occurred over 1 year, and the incidence of PAEs was lower compared with levetiracetam.
Keyphrases
  • drug resistant
  • clinical practice
  • multidrug resistant
  • acinetobacter baumannii
  • risk factors
  • cross sectional
  • african american
  • clinical trial
  • pseudomonas aeruginosa
  • temporal lobe epilepsy